In the OAK trial, assessing the efficacy of the anti-PD-L1 antibody, atezolizumab, until progression or unacceptable toxicity in previously treated advanced NSCLC, regardless of PD-L1 expression, patients, 28% of those in the experimental arm demonstrated long-term survival, defined as greater or equal to 24 months (10). The gene discussed is CD274; the disease is non-small cell lung carcinoma.